These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 30531684)

  • 21. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
    Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
    Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased STAT1 Expression in High Grade Serous Ovarian Cancer Is Associated With a Better Outcome.
    Josahkian JA; Saggioro FP; Vidotto T; Ventura HT; Candido Dos Reis FJ; de Sousa CB; Tiezzi DG; de Andrade JM; Koti M; Squire JA
    Int J Gynecol Cancer; 2018 Mar; 28(3):459-465. PubMed ID: 29303938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
    Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
    Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biological and prognostic value of ETV5 in high-grade serous ovarian cancer.
    Zhang L; Fu R; Liu P; Wang L; Liang W; Zou H; Jia W; Tao L
    J Ovarian Res; 2021 Nov; 14(1):149. PubMed ID: 34736492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High expression of Tie-2 predicts poor prognosis in primary high grade serous ovarian cancer.
    Sopo M; Sallinen H; Hämäläinen K; Kivelä A; Ylä-Herttuala S; Kosma VM; Keski-Nisula L; Anttila M
    PLoS One; 2020; 15(11):e0241484. PubMed ID: 33151982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Engrailed-2 (EN2) - a novel biomarker in epithelial ovarian cancer.
    McGrath SE; Annels N; Madhuri TK; Tailor A; Butler-Manuel SA; Morgan R; Pandha H; Michael A
    BMC Cancer; 2018 Oct; 18(1):943. PubMed ID: 30285763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MRPL15 is a novel prognostic biomarker and therapeutic target for epithelial ovarian cancer.
    Xu H; Zou R; Li F; Liu J; Luan N; Wang S; Zhu L
    Cancer Med; 2021 Jun; 10(11):3655-3673. PubMed ID: 33934540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A distinctive ovarian cancer molecular subgroup characterized by poor prognosis and somatic focal copy number amplifications at chromosome 19.
    Sung CO; Song IH; Sohn I
    Gynecol Oncol; 2014 Feb; 132(2):343-50. PubMed ID: 24321399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
    Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
    Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study.
    Brunette LL; Mhawech-Fauceglia PY; Ji L; Skeate JG; Brand HE; Lawrenson K; Walia S; Chiriva-Internati M; Groshen S; Roman LD; Kast WM; Da Silva DM
    BMC Cancer; 2018 Oct; 18(1):970. PubMed ID: 30309325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.
    Yang M; Xie X; Ding Y
    Oncol Rep; 2016 Mar; 35(3):1796-806. PubMed ID: 26750614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression and clinical significance of transcription factor 4 (TCF4) in epithelial ovarian cancer.
    Liu L; Zeng Z; Yi J; Zuo L; Lv J; Yuan J; Lin Z; Luo R; Feng X
    Cancer Biomark; 2019; 24(2):213-221. PubMed ID: 30614797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ZNF671 DNA methylation as a molecular predictor for the early recurrence of serous ovarian cancer.
    Mase S; Shinjo K; Totani H; Katsushima K; Arakawa A; Takahashi S; Lai HC; Lin RI; Chan MWY; Sugiura-Ogasawara M; Kondo Y
    Cancer Sci; 2019 Mar; 110(3):1105-1116. PubMed ID: 30633424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Upregulation of cyclase-associated actin cytoskeleton regulatory protein 2 in epithelial ovarian cancer correlates with aggressive histologic types and worse outcomes.
    Adachi M; Masugi Y; Yamazaki K; Emoto K; Kobayashi Y; Tominaga E; Banno K; Aoki D; Sakamoto M
    Jpn J Clin Oncol; 2020 Jun; 50(6):643-652. PubMed ID: 32211793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
    Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
    Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A retrospective analysis of immunohistochemically determined IRF4 (interferon regulating factor 4) expression in a consecutive cohort of 114 ovarian cancer patients.
    Heimes AS; Schmidt M; Jäkel J; Almstedt K; Gebhard S; Weyer-Eiberich V; Elger T; Krajnak S; Brenner W; Hasenburg A; Battista MJ
    Arch Gynecol Obstet; 2019 Jan; 299(1):239-246. PubMed ID: 30357498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma.
    Cui X; Li L; Yan G; Meng K; Lin Z; Nan Y; Jin G; Li C
    BMC Cancer; 2015 Apr; 15():244. PubMed ID: 25885439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma.
    Chen X; Wang X; Wei X; Wang J
    J Ovarian Res; 2016 Nov; 9(1):83. PubMed ID: 27887627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer.
    Sopo M; Anttila M; Hämäläinen K; Kivelä A; Ylä-Herttuala S; Kosma VM; Keski-Nisula L; Sallinen H
    BMC Cancer; 2019 Jun; 19(1):584. PubMed ID: 31200683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aberrant S100A16 expression might be an independent prognostic indicator of unfavorable survival in non-small cell lung adenocarcinoma.
    Chen D; Luo L; Liang C
    PLoS One; 2018; 13(5):e0197402. PubMed ID: 29746588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.